However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.
CO2-udledningen for det danske medicinalselskab Novo Nordisk er steget i løbet af 2024. Det skriver Ritzau. CO2-udledningen for det danske medicinalselskab Novo Nordisk er steget i løbet af 2024. Det ...
Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.
Regeringen og Novo Nordisk Fonden er netop blevet enige om, hvordan de ti milliarder kroner, fonden har givet til den grønne ...
Bagsværd, Denmark, 27 January 2025 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
I anledningen af den portugiske fodboldspiller Cristiano Ronaldos 40 års fødselsdag den 5. februar, blev en 3,5 meter høj ...
Instruktør og tidligere rektor for Filmskolen Jens Ravn er død. Han døde natten til tirsdag på et hospital i Frankrig og blev ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback